Randomized clinical trial of aspirin and simvastatin for pulmonary arterial hypertension: ASA-STAT

Circulation

Volumn 123, Issue 25, 2011, Pages 2985-2993

  Kawut, Steven M ^a,b   Bagiella, Emilia ^b   Lederer, David J ^b   Shimbo, Daichi ^b   Horn, Evelyn M ^e   Roberts, Kari E ^f   Hill, Nicholas S ^f   Barr, R Graham ^b,c   Rosenzweig, Erika B ^d   Post, Wendy ^g   Tracy, Russell P ^h   Palevsky, Harold I ^a   Hassoun, Paul M ^g   Girgis, Reda E ^g  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b University of Pennsylvania School of Medicine ^*  (United States)

^c Department of Biostatistics ^*  (United States)

^d Joseph L Mailman School of Public Health ^*  (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

^f TUFTS MEDICAL CENTER   (United States)

^g JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

antiplatelet agents; clinical trial; endothelial dysfunction; hypertension pulmonary; statins

Indexed keywords

ACETYLSALICYLIC ACID; PLACEBO; SIMVASTATIN;

ADULT; ARTHRALGIA; ARTICLE; BLEEDING; CONTROLLED STUDY; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; EPIGASTRIC PAIN; FEMALE; HEADACHE; HUMAN; INFECTION; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; SKIN BRUISING; STOMACH HEMORRHAGE; STOMACH ULCER; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WALKING;

ADULT; ASPIRIN; CHOLESTEROL; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; EXERCISE TOLERANCE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SIMVASTATIN; TREATMENT OUTCOME; WALKING;

EID: 79960020590     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.110.015693     Document Type: Article

References (43)

1. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, Groves BM, Loyd JE. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;327:70-75.
2. Robbins IM, Kawut SM, Yung D, Reilly MP, Lloyd W, Cunningham G, Loscalzo J, Kimmel SE, Christman BW, Barst RJ. A study of aspirin and clopidogrel in idiopathic pulmonary arterial hypertension. Eur Respir J. 2006;27:578-584. (Pubitemid 43372533)
3. Adatia I, Barrow SE, Stratton PD, Miall-Allen VM, Ritter JM, Haworth SG. Thromboxane A2 and prostacyclin biosynthesis in children and adolescents with pulmonary vascular disease. Circulation. 1993;88: 2117-2122. (Pubitemid 23326090)
4. Barst RJ, Stalcup SA, Steeg CN, Hall JC, Frosolono MF, Cato AE, Mellins RB. Relation of arachidonate metabolites to abnormal control of the pulmonary circulation in a child. Am Rev Respir Dis. 1985;131: 171-177. (Pubitemid 15161988)
5. Ichida F, Uese K, Hamamichi Y, Hashimoto I, Tsubata S, Fukahara K, Murakami A, Miyawaki T. Chronic effects of oral prostacyclin analogue on thromboxane A2 and prostacyclin metabolites in pulmonary hypertension. Acta Paediatr Jpn. 1998;40:14-19. (Pubitemid 28120287)
6. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, Koerner SK, Langleben D, Keller CA, Murali S, Uretsky BF, Clayton LM, Jöbsis MM, Blackburn SD Jr, Shortino D, Crow JW. A comparison of continuous intravenous epoprostenol with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-302.
7. McLaughlin VV, Benza RL, Rubin LJ, Channick RN, Voswinckel R, Tapson VF, Robbins IM, Olschewski H, Rubenfire M, Seeger W. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2010;55:1915-1922.
8. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ, Nikkho S, Speich R, Hoeper MM, Behr J, Winkler J, Sitbon O, Popov W, Ghofrani HA, Manes A, Kiely DG, Ewert R, Meyer A, Corris PA, Delcroix M, Gomez-Sanchez M, Siedentop H, Seeger W. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329. (Pubitemid 34815354)
9. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC, Keogh A, Oudiz R, Frost A, Blackburn SD, Crow JW, Rubin LJ. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med. 2002; 165:800-804. (Pubitemid 34229650)
10. Lopes AA, Maeda NY, Almeida A, Jaeger R, Ebaid M, Chamone DF. Circulating platelet aggregates indicative of in vivo platelet activation in pulmonary hypertension. Angiology. 1993;44:701-706. (Pubitemid 23263729)
11. Nakonechnicov S, Gabbasov Z, Chazova I, Popov E, Belenkov Y. Platelet aggregation in patients with primary pulmonary hypertension. Blood Coagul Fibrinolysis. 1996;7:225-227. (Pubitemid 26167950)
12. Damas JK, Otterdal K, Yndestad A, Aass H, Solum NO, Froland SS, Simonsen S, Aukrust P, Andreassen AK. Soluble CD40 ligand in pulmonary arterial hypertension: possible pathogenic role of the interaction between platelets and endothelial cells. Circulation. 2004;110:999-1005. (Pubitemid 39136216)
13. Sakamaki F, Kyotani S, Nagaya N, Sato N, Oya H, Satoh T, Nakanishi N. Increased plasma P-selectin and decreased thrombomodulin in pulmonary arterial hypertension were improved by continuous prostacyclin therapy. Circulation. 2000;102:2720-2725.
14. Stuard ID, Heusinkveld RS, Moss AJ. Microangiopathic hemolytic anemia and thrombocytopenia in primary pulmonary hypertension. N Engl J Med. 1972;287:869-870.
15. Suzuki H, Nakasato M, Sato S, Yokoyama S, Katsuura M, Yamaki S, Hayasaka K. Microangiopathic hemolytic anemia and thrombocytopenia in a child with atrial septal defect and pulmonary hypertension. Tohoku J Exp Med. 1997;181:379-384. (Pubitemid 27204693)
16. Chin KM, Channick RN, de Lemos JA, Kim NH, Torres F, Rubin LJ. Hemodynamics and epoprostenol use are associated with thrombocytopenia in pulmonary arterial hypertension. Chest. 2009;135:130-136.
17. Shen L, Shen J, Pu J, He B. Aspirin attenuates pulmonary arterial hypertension in rats by reducing plasma 5-hydroxytryptamine levels. Cell Biochem Biophys. Published online before print February 15, 2011. doi: 10.1007/s12013-011-9156-x. http://www.springerlink.com/content/ j46q803525t58452/. Accessed March 15, 2011.
18. Bowers R, Cool C, Murphy RC, Tuder RM, Hopken MW, Flores SC, Voelkel NF. Oxidative stress in severe pulmonary hypertension. Am J Respir Crit Care Med. 2004;169:764-769. (Pubitemid 38338929)
19. Mittal M, Roth M, Konig P, Hofmann S, Dony E, Goyal P, Selbitz AC, Schermuly RT, Ghofrani HA, Kwapiszewska G, Kummer W, Klepetko W, Hoda MA, Fink L, Hanze J, Seeger W, Grimminger F, Schmidt HH, Weissmann N. Hypoxia-dependent regulation of nonphagocytic NADPH oxidase subunit NOX4 in the pulmonary vasculature. Circ Res. 2007;101: 258-267. (Pubitemid 47344075)
20. Endres M, Laufs U, Huang Z, Nakamura T, Huang P, Moskowitz MA, Liao JK. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci USA. 1998;95:8880-8885. (Pubitemid 28350583)
21. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest. 1998;101:2711-2719. (Pubitemid 28294580)
22. Jacobson JR, Dudek SM, Birukov KG, Ye SQ, Grigoryev DN, Girgis RE, Garcia JG. Cytoskeletal activation and altered gene expression in endothelial barrier regulation by simvastatin. Am J Respir Cell Mol Biol. 2004;30:662-670. (Pubitemid 38591217)
23. Laufs U, La Fata V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 1998;97:1129-1135. (Pubitemid 28152885)
24. Laufs U, Marra D, Node K, Liao JK. 3-Hydroxy-3-methylglutaryl-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing rho GTPase-induced down-regulation of p27(Kip1). J Biol Chem. 1999;274:21926-21931.
25. Girgis RE, Mozammel S, Champion HC, Li D, Peng X, Shimoda L, Tuder RM, Johns RA, Hassoun PM. Regression of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Lung Cell Mol Physiol. 2007;292:L1105-L1110. (Pubitemid 47084854)
26. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L, Qiu D, Benson G, Pearl RG, Kao PN. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation. 2003;108:1640-1645. (Pubitemid 37187793)
27. Kuang T, Wang J, Pang B, Huang X, Burg ED, Yuan JX, Wang C. Combination of sildenafil and simvastatin ameliorates monocrotaline-induced pulmonary hypertension in rats. Pulm Pharmacol Ther. 2010;23:456-464.
28. Lee DS, Kim YK, Jung YW. Simvastatin, sildenafil and their combination in monocrotaline induced pulmonary arterial hypertension. Korean Circ J. 2010;40:659-664.
29. Wright JL, Zhou S, Preobrazhenska O, Marshall C, Sin DD, Laher I, Golbidi S, Churg AM. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am J Respir Crit Care Med. 2011;183:50-58.
30. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG, Kao PN. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med. 2002;166: 1403-1408. (Pubitemid 35292709)
31. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM, Johns RA. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol. 2003;285:H938-H945. (Pubitemid 37048146)
32. Taraseviciene-Stewart L, Scerbavicius R, Choe KH, Cool C, Wood K, Tuder RM, Burns N, Kasper M, Voelkel NF. Simvastatin causes endothelial cell apoptosis and attenuates severe pulmonary hypertension. Am J Physiol Lung Cell Mol Physiol. 2006;291:L668-L676. (Pubitemid 44498478)
33. King WT, Day RW. Treatment of pediatric pulmonary hypertension with simvastatin: an observational study. Pediatr Pulmonol. Published online before print October 21, 2010. doi:10.1002/ppul.21361. http:// onlinelibrary.wiley.com/ doi/10.1002/ppul.21361/abstract. Accessed March 15, 2011.
34. Kao PN. Simvastatin treatment of pulmonary hypertension: an observational case series. Chest. 2005;127:1446-1452. (Pubitemid 46224314)
35. Wilkins MR, Ali O, Bradlow W, Wharton J, Taegtmeyer A, Rhodes CJ, Ghofrani HA, Howard L, Nihoyannopoulos P, Mohiaddin RH, Gibbs JS. Simvastatin as a treatment for pulmonary hypertension trial. Am J Respir Crit Care Med. 2010;181:1106-1113.
36. Kawut SM, Bagiella E, Shimbo D, Lederer DJ, Al-Naamani N, Roberts KE, Barr RG, Post W, Horn EM, Tracy R, Hassoun PM, Girgis RE. Rationale and design of a phase II clinical trial of aspirin and simvastatin for the treatment of pulmonary arterial hypertension: ASA-STAT. Contemp Clin Trials. 2011;32:280-287.
37. Langleben D, Christman BW, Barst RJ, Dias VC, Galie N, Higenbottam TW, Kneussl M, Korducki L, Naeije R, Riedel A, Simonneau G, Hirsch AM, Rich S, Robbins IM, Oudiz R, McGoon MD, Badesch DB, Levy RD, Mehta S, Seeger W, Soler M. Effects of the thromboxane synthetase inhibitor and receptor antagonist terbogrel in patients with primary pulmonary hypertension. Am Heart J. 2002;143:E4.
38. Clarke RJ, Mayo G, Price P, FitzGerald GA. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N Engl J Med. 1991;325:1137-1141.
39. Girgis RE, Ma SF, Ye S, Grigoryev DN, Li D, Hassoun PM, Tuder RM, Johns RA, Garcia JG. Differential gene expression in chronic hypoxic pulmonary hypertension: effect of simvastatin treatment. Chest. 2005; 128:579S. (Pubitemid 43054134)
40. McMurtry MS, Bonnet S, Michelakis ED, Bonnet S, Haromy A, Archer SL. Statin therapy, alone or with rapamycin, does not reverse monocrotaline pulmonary arterial hypertension: the rapamycin-atorvastatin-simvastatin study. Am J Physiol Lung Cell Mol Physiol. 2007;293: L933-L940. (Pubitemid 47572241)
41. Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol. 2008;294: H801-H809. (Pubitemid 351253291)
42. Barreto AC, Maeda NY, Soares RP, Cicero C, Lopes AA. Rosuvastatin and vascular dysfunction markers in pulmonary arterial hypertension. Braz J Med Biol Res. 2008;41:657-663.
43. Ventetuolo CE, Benza RL, Peacock AJ, Zamanian RT, Badesch DB, Kawut SM. Surrogate and combined end points in pulmonary arterial hypertension. Proc Am Thorac Soc. 2008;5:617-622. (Pubitemid 352031534)